Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy

Nature Clinical Practice Oncology

Volumn 5, Issue 8, 2008, Pages 487-491

  Plotkin, Scott R ^a   Singh, Marybeth A ^a   O'Donnell, Caroline C ^a   Harris, Gordon J ^a,b   McClatchey, Andrea I ^a   Halpin, Chris ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB;

ACOUSTIC NEURINOMA; ADULT; ARTICLE; AUDIOMETRY; CANCER SURGERY; CASE REPORT; DISEASE DURATION; DRUG RESPONSE; FAMILY HISTORY; HEARING AID; HEARING LOSS; HUMAN; MALE; MEDICAL EXAMINATION; NEUROFIBROMATOSIS; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHONEME; PRIORITY JOURNAL; TINNITUS;

AUDIOMETRY, PURE-TONE; AUDITORY THRESHOLD; COCHLEAR IMPLANTATION; COMBINED MODALITY THERAPY; EAR NEOPLASMS; HEARING LOSS, SENSORINEURAL; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROFIBROMATOSIS 2; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TREATMENT OUTCOME; VESTIBULAR DISEASES;

EID: 48649110199     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1157     Document Type: Article

References (18)

1. Curto M et al. (2007) Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol 177: 893-903
2. Sorensen AG et al. (2001) Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol 19: 551-557
3. American National Standards Institute (2004) Methods for manual pure-tone threshold audiometry. S3.21 New York: ANSI
4. Boothroyd A and Calkwell S (1981) Vibrotactile thresholds in pure-tone audiometry. In Hearing Measurement: A Book of Readings, edn 2 134-139 (Eds Chaiklin JB et al.) New York: Addison Wesley
5. Halpin C: Measuring audiometric outcomes. In Evidence Based Otolaryngology 227-238 (Eds Shin J et al.) New York: Springer, in press
6. Owens E et al. (1982) Interim assessment of candidates for cochlear implants. Arch Otolaryngol 108. 478-483
7. Boothroyd A et al. (1988) Voice fundamental frequency as an auditory supplement to the speechreading of sentences. Ear Hear 9: 306-312
8. Farrell CJ and Plotkin SR (2007) Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hipp6-Lindau, and other syndromes. Neurol Clin 25: 925-946
9. Evans DG et al. (2005) Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10 year period: higher incidence than previously thought. Otol Neurotol 26: 93-97
10. Mulvihill JJ et al. (1990) NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med 113: 39-52
11. National Institutes of Health Consensus Development Conference (1988) Neurofibromatosis. Conference statement. Arch Neurol 45: 575-578
12. Baser ME et al. (2002) Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 59: 1759-1765
13. Evans DG et al. (2005) Management of the patient and family with neurofibromatosis 2: A consensus conference statement. Br J Nerosurg 19: 5-12
14. Otto SR et al. (2002) Multichannel auditory brainstem implant: update on performance in 61 patients. J Neurosurg 96: 1063-1071
15. Mathieu D et al. (2007) Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: An analysis of tumor control, complications, and hearing preservation rates. Neurosurgery 60: 460-468
16. Rowe JG et al. (2003) Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis. J Neurol Neurosurg Psychiatry 74: 1288-1293
17. Evans DG et al. (2006) Malignant transformation and new primary tumours after therapeutic radiation for benign disease: Substantial risks in certain tumour prone syndromes. J Med Genet 43: 289-294
18. Shepherd FA et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132 Diagnosis: Progressive neurofibromatosis-type-2-related vestibular schwannomas. Management: Annual cranial MRI and audiology, surgical resection of right vestibular schwannoma, high-power behind-the-ear hearing aid, erlotinib therapy for progressive left vestibular schwannoma.